Methods and compositions for treating malignant tumors associated with KRAS mutation

USRE49229E1 · kind E1 · reissue

Assignee

• NITTO DENKO CORPORATION · JP

Inventors

• Kenjirou Minomi · Osaka, JP
• Jihua Liu · San Marcos, US
• Li-Ting Wang · Meekrap-oord, CN
• Bharat Majeti · San Diego, US
• Roger Adami · Bothell, US
• Wenbin Ying · San Diego, US

Key dates

• Filing date: Feb 28, 2020
• Grant date: Oct 4, 2022
• Expiry date: Feb 28, 2040

Classification

• Technology area (CPC —): General

Abstract

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.